Thus, inhibition of the PI3K/AKT axis showed antitumor effects in prostate cancer, lung cancer, as well as breast cancer cells, and AKT inhibitors, such as MK2206, Perifosine, or Ipatasertib, are widely tested in clinical trials [34,38,39,40]. The gene discussed is AKT1; the disease is prostate carcinoma.